Moteur de recherche d’entreprises européennes
Financement de l’UE (3 962 143 €) : Nouveau dispositif à base de biomatériaux pour le traitement de la SEP progressive - Une approche paneuropéenne intégrée Hor01/05/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Nouveau dispositif à base de biomatériaux pour le traitement de la SEP progressive - Une approche paneuropéenne intégrée
PMSMatTrain is focusing on gaining a comprehensive understanding of the progressive (late degenerative phase) of multiple sclerosis (PMS) from basics to translation, fully supported by 8 beneficiaries (6 research institutions, 2 SMEs). Recruited ESRs will receive compulsory discipline-specific, generic and complementary transferable skills training. PMSMatTrain’s Joint Research Education and Training programme (JRTP) will provide early stage researchers with high quality research and transferable skills training in intellectual property, leadership skills, innovation, regulatory affairs, entrepreneurship, gender policy, and medical device evaluation, which will ensure that they are immediately employable in industry. The consortium will develop a multi-modal hyaluronan-based medical device designed to release small molecular weight anti-inflammatory molecules (APRIL and sPIF) followed by remyelination and neuroprotective drugs (ibudilast and miconazole). PMSMatTrain will for the first time utilise these functionalised multi-modal biomimetic hyaluronan scaffolds as a tool to investigate cross-talk between signals arising due to chronic neuroinflammation and those leading to demyelination and axonal loss, while identifying molecular mechanisms that facilitate remyelination and neuroprotection in PMS. This approach could yield the first cortex-proximal and directed biomaterials-based disease-modifying therapy for PMS. These scaffolds will be tested in state of the art MS patient induced stem cell-derived oligodendrocyte cultures and organotypic cultures to investigate MS pathophysiology. In vivo responses will be characterised using field-leading MRI and mass spectrophotometry protocols. PMSMatTrain will also generate a clinically-relevant in silico model of drug elusion and dispersal within the CNS. Our industry partners will develop the end-device by providing standardised manufacturing protocols for scaled-up production and commercialisation of the cGMP product.
| Contipro AS | 234 872 € |
| Neos Surgery SL | 501 810 € |
| Syddansk Universitet | 297 522 € |
| Universita Degli Studi Gabriele D'Annunzio Di Chieti-Pescara | 261 500 € |
| UNIVERSITAET MUENSTER | 505 577 € |
| Universite Grenoble Alpes | 274 802 € |
| Universiteit Antwerpen | 512 640 € |
| University of Galway | 1 373 422 € |
https://cordis.europa.eu/project/id/813263
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
